— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
Most Popular
Verizon Communications (VZ) Q1 2024 Earnings: Key financials and quarterly highlights
Verizon Communications Inc. (NYSE: VZ) reported first quarter 2024 earnings results today. Total operating revenue was $33 billion, up 0.2% from the same period last year. Net income attributable to
NextTrip stands out as one of the most descriptive names in travel sector: CEO
NextTrip, Inc. (NASDAQ: NTRP) is a technology-driven travel agency that offers travel booking and interactive travel media solutions. The online platform allows travelers to book accommodation and transportation services including
What to look for when American Airlines (AAL) reports Q1 2024 earnings results
Shares of American Airlines Group Inc. (NASDAQ: AAL) rose 1% on Friday. The stock has gained over 3% over the past three months. The airline is scheduled to report its first